

Country Meeting

Prevention and control of HPV and HPV
related cancers in France: the current
landscape and way forward

2-3 December, 2021

VEYRIER-DU-LAC, ANNECY, FRANCE



Viral Hepatitis Prevention Board

[VHPB News](#) | [About us](#) | [Meetings](#) | [Publications](#) | [Resources](#) | [Links](#) | [Contact us](#)

search

VHPB Meetings

Pre-meeting documents

Presentations

Meeting output

Prevention and control of viral hepatitis in Spain: Lessons learnt and the way forward

▶ 2006 November | Madrid, Spain

Prevention and control of perinatal hepatitis B virus (HBV) transmission in the WHO European Region

▶ 2006 March | Istanbul, Turkey

Can the United Kingdom control viral hepatitis?

▶ 2005 November | Edinburgh, United Kingdom

Hepatitis B, hepatitis C, and other blood-borne infections in healthcare workers

▶ 2005 March | Rome, Italy

Prevention and control of viral hepatitis in France: Lessons learnt and the way forward

▶ 2004 November | Veyrier-Du-Lac, France

Strengthening immunisation systems and introduction of hepatitis B vaccine in Central and Eastern Europe and the Newly Independent States

▶ 2004 May | Kyiv, Ukraine



VIRAL HEPATITIS

PUBLISHED BY THE VIRAL HEPATITIS PREVENTION BOARD (VHPB)

March 2005
Volume 13 - Number 2

CONTENTS

EDITORIAL	1
The healthcare system in France	2
National strategy for prevention and control of viral hepatitis infection in France	3
Hepatitis A in France	5
Hepatitis B in France	5
Epidemiology of hepatitis B in France	5
Hepatitis B surveillance	5
Hepatitis B immunisation policy	6
Prevention and residual risk of HBV infection following blood transfusions	7
Preventive measures against HBV infection in healthcare workers	7
Preventive measures for prisoners	8
Hepatitis C in France	9
Epidemiology of hepatitis C in France	9
Hepatitis C surveillance	9
Screening	9
Preventive measures for injection drug users	

Editorial

This issue of *Viral Hepatitis* takes a look at prevention and control of viral hepatitis in France, based on conclusions that were reached during the VHPB meeting that was held November 18-19, 2004 in Veyrier-du-Lac, France.

Achievements of France's national hepatitis programmes

Since the early 1990s, prevention and control of viral hepatitis was already considered a public health priority in France. During the last decade, much progress has been made in reducing morbidity and mortality due to viral hepatitis. France's national hepatitis programmes have resulted in more effective screening campaigns, enhanced hepatitis surveillance systems, an improved network of thirty-one hepatology reference centres, and excellent hepatitis research programmes that are funded by a wide range of sources, some of which include the ANRS / ANRH, the European Commission, and external grants and scholarships. Some of the most successful achievements of France's viral hepatitis programmes are the newly enhanced capacity for diagnosing larger numbers of patients and the currently easy access to therapy with costs to patients that are fully reimbursed.

France's new public health policy law

A new public health law, enacted in August 2004, will help to reinforce coordination and synergy among institutions and other key players, with prevention programmes that will also be implemented at regional level. The aims of this new law are to improve public health through prevention of avoidable and premature morbidity and mortality, maintaining quality of life among the disabled, and reducing disparities and inequalities within the healthcare sector.

HPV Prevention and Control Board



HPV Prevention
and Control Board

www.hpvboard.org

Mission, Goal & Objectives

1. Mission:

Generate, multiply and disseminate relevant information on HPV to a broad array of stakeholders.

2. Goal:

Contribute to the control of HPV infection and to the prevention and screening of HPV related cancers.

3. Objectives:

Providing evidence-based guidance on key technical and strategic issues.

Monitoring the progress of HPV control programs at the country and regional levels.



A multi-disciplinary Board formed by prominent experts

- Act in their personal capacity
- Are often affiliated with stake holding partners
- This provides open and honest discussions
- Advisors and speakers at HPV Prevention & Control Board meetings are not paid
- No formal organisation with president, vice-president etc : minimal bureaucratic structure

Advisors:

- Dr. Narendra Arora, India
- Dr. Marc Arbyn, Scientific Institute of Public Health, Belgium
- Prof. dr. Paolo Bonanni, University of Florence, Italy
- Dr. Xavier Bosch, Catalan Institute of Oncology (ICO), Spain
- Dr. Kate Cuschieri, Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Scotland, UK
- Prof. Mamadou Diop, Director of the Joliot Curie Cancer institute of Dakar, Senegal
- Dr. Silvia de Sanjosé, Catalan Institute of Oncology (ICO), Spain
- Prof. dr. Eduardo Franco, McGill University, Canada
- Prof. Suzanne Garland, Australia
- Prof. Dr. Anna Giuliano, Moffitt Cancer Center, USA
- Dr. Mark Kane, Consultant, USA



A multi-disciplinary Board formed by prominent experts

Advisors:

- Prof. dr. Mira Kojouharova, National Centre of Infectious and Parasitic Diseases (NCIPD), Bulgaria
- Prof. dr. Susanne Krüger Kjaer, University of Copenhagen, Denmark
- Dr. Heidi Larson, London School of Hygiene and Tropical Medicine, UK
- Prof. dr. Pier Luigi Lopalco, Italy
- Prof. dr. Nubia Muñoz, Em. Prof of the National Cancer Institute of Colombia
- Prof. dr. Mario Poljak, Institute of Microbiology and Immunology, clinical Microbiology, Slovenia
- Prof. Dr. Margaret Stanley, University of Cambridge, UK
- Prof. Dr. Pierre Van Damme, University of Antwerp, Belgium
- Dr. Alex Vorsters, University of Antwerp, Belgium
- Dr. Sharon Hanley, Hokkaido University, Japan

Observers:

- Dr. Iacobo Baussano, IACR
- Dr. Nedret Emiroglu, WHO Euro
- Mr. Tarik Derrough, ECDC
- Dr. Liudmila Mosina , WHO Euro
- Dr. Lauri Markowitz, CDC, USA



Supported by a permanent & dynamic Scientific Secretariat:

- Personnel involved*:
 - Brenda Janssens, Xenia Mikulla
 - Greet Hendrickx
 - Sara Valckx
 - Dur-e-Nayab Waheed
 - Alex Vorsters
- Executive Secretary: Pierre Van Damme



- Located within the facilities of the Centre for the Evaluation of Vaccination (CEV), University of Antwerp

*: Total involvement of 2.0 FTE, all member have other tasks at the department.



Secretariat implements:

➤ Preparation and organisation of meetings


➤ Publications

➤ Media activities

➤ Website: www.hpvboard.org

➤ Participation in third party meetings

➤ All financial issues are done by the rules of the University of Antwerp



Permanent intensive communication between HPV board members and secretariat



HPV PREVENTION AND CONTROL BOARD

- About us
- Meetings
- Resources
- Vaccine safety
- News

HPV Prevention and Control Board



The HPV Prevention and Control Board was created in December 2015 with the aim to share relevant information on HPV with a broad array of stakeholders.

www.uantwerpen.be/en/projects/hpv-prevention-and-control-board/meetings/



HPV Prevention and Control Board Kick-Off meeting 1-2 December 2015



**Barriers in HPV Vaccination & cervical screening programmes.
27-28 June 2016 Meeting Antwerp:**



**Country meeting: 'Prevention and control of HPV and HPV related cancers in Denmark: lessons learnt and the way forward'
17-18 November 2016, Copenhagen, Denmark**



**Technical meeting: Symposium: Building Trust, Managing Risk:
Vaccine Confidence and Human Papillomavirus Vaccination,
7-8 June 2017, London, UK**



Country meeting: 'Prevention and control of HPV and HPV related cancers in Ireland and the UK: lessons learnt and the way forward'

30th November – 1 December 2017, Dublin, Ireland.



As the meeting was held in Dublin, we had the honour to have Mr Simon Harris, Minister of Health of Ireland, open the meeting. In his [speech](#), he reiterated his full support to the HPV vaccination programme in Ireland and emphasized the role of qualified medical professionals



**Technical meeting: Prevention and control of HPV and HPV related cancers: the role of HCW in the HPV vaccination and screening program implementation',
15 - 16 May 2018, Bucharest, Romania**



**Country meeting: 'Prevention and control of HPV and HPV related cancers in Colombia: lessons learnt and the way forward'
15-16 November 2018, Bogotá, Colombia**



**HPV Vaccination of Adults: Impact, Opportunities and Challenges.
14-15 November 2019, Antwerp, Belgium**

**Challenges in the HPV Screening Landscape, Triage of Screening
Positive Samples, and Screening in the Era of Vaccination.
27-28 August 2020, Antwerp, Belgium**

**Impact of COVID-19 on Cervical Cancer Screening, Treatment and
Vaccination.
12-13 November 2020, Antwerp, Belgium**

**Reinforcing Access to HPV Vaccination & Cervical Cancer Screening
and Treatment.
15-16 April 2021, Antwerp, Belgium**



The role of HCP in HPV vaccination and screening programme implementation - Prevention and control of HPV and HPV related cancers in Romania, 15 & 16 May 2018

Short Videos



Benefits and Safety of HPV Vaccination
- Dr. Xavier Bosch



USA - Helping healthcare providers
improve HPV communication - Dr. Noel
Brewer



HPV Vaccination of Adults : Impact, Opportunities and Challenges. 14 & 15 Nov 2019

Videos



Potential Benefits of HPV Vaccine in sexually active women: delivering the promise - John Schiller



Towards cervical cancer elimination: the context of HPV Vaccination - Paul Bloem



Publications in scientific journals

Papillomavirus Research:

Manuscript on 'Overcoming barriers in HPV vaccination and screening programs'

Vaccine:

HPV Immunization programs: Ensuring their sustainability and resilience.

Papilloma Virus Research:

The Role of healthcare providers in HPV Vaccination Programs- A meeting report



Papillomavirus Research

Volume 4, December 2017, Pages 45-53

[open access](#)



Overcoming barriers in HPV vaccination and screening programs

Alex Vorsters ^a ✉, Marc Arbyn ^b, Marc Baay ^c, Xavier Bosch ^d, Silvia de Sanjosé ^{d, e}, Sharon Hanley ^f, Emilie Karafillakis ^g, Pier Luigi Lopalco ^h, Kevin G. Pollock ⁱ, Joanne Yarwood ^j, Pierre Van Damme ^a

Vaccine 36 (2018) 5219–5221



Contents lists available at ScienceDirect

Vaccine

journal homepage: www.elsevier.com/locate/vaccine



Commentary

HPV immunization programs: Ensuring their sustainability and resilience

Alex Vorsters ^{*}, Pierre Van Damme

Centre for the Evaluation of Vaccination, University of Antwerp, Belgium



Papillomavirus Research

Volume 8, December 2019, 100183



The role of healthcare providers in HPV vaccination programs – A meeting report



Publications in scientific journals

BMC Proceedings:

Prevention and control of HPV infection and HPV-related cancers in Colombia.

Vorsters et al. *BMC Proceedings* 2020, **14**(Suppl 9):8
<https://doi.org/10.1186/s12919-020-00192-2>

BMC Proceedings

MEETING REPORT

Open Access

Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report



Alex Vorsters^{1*}, Francesc Xavier Bosch^{2,3}, Paolo Bonanni⁴, Eduardo L. Franco⁵, Marc Baay⁶, Clarissa Simas⁷, Dur-e-Nayab Waheed¹, Carlos Castro⁸, Raul Murillo⁹, Lina Trujillo¹⁰, Carolina Wiesner¹⁰ and Nubia Muñoz¹⁰

From Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward Bogota, Colombia. 15-16 November 2018

Acta Dermatovenerologica

Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Acta Dermatovenerol APA

Acta Dermatovenerologica
Alpina, Pannonica et Adriatica

2021;30:21-26
doi: 10.15570/actaapa.2021.5

Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Mario Poljak¹, Kate Cuschieri², Dur-e-Nayab Waheed³, Marc Baay⁴, Alex Vorsters^{3,5}

¹Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. ²Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian Scotland, Edinburgh, United Kingdom. ³Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Wilrijk, Belgium. ⁴Pg5 Epidemiology & Pharmacovigilance, Leuven, Belgium.



Country Meeting

Prevention and control of HPV and HPV related cancers in France: the current landscape and way forward

2 - 3 December, 2021
Annecy, France

BACKGROUND DOCUMENT

Draft Version

Dur-e-Nayab Waheed and Alex Vorsters


HPV Prevention & Control Board

Executive Secretariat, Vaccine and Infectious disease Institute, University of Antwerp, Campus Drie Eiken,
Universiteitsplein 1, 2610 Antwerp, Belgium.

Comments can be addressed to hpvboard.secretariat@uantwerpen.be

Content

<i>Part 1: PubMed/ Medline Search by Topic</i>	1
<i>Prevention and control of HPV and HPV related cancers in France: the current landscape and way forward</i>	1
<i>Part 2: Bibliography of Speakers</i>	38
Agathe Billette de Villemeur, expert member at HAS CTV & HCSP	39
Anne Garnier, Medical coordinator. Regional referent for cervical screening, Centre Regional de Coordination des Dépistages des Cancers. Site de l'Isère	39
Anne-Sophie Woronoff, Head of the Doubs Cancer Registry, Besançon CHU, Registre des tumeurs du Doubs	40
Catherine Weil Olivier, Independent Expert, Honorary Professor of paediatrics, University Paris 7, France	41
Claire Grenier, Medical Advisor to the Rector, French Guyana Academy, National Education	42
Emilie Karafillakis, European Research Lead, Vaccine Confidence Project, London School of Hygiene & Tropical Medicine	42
Jean Levêque, Head of the Department – Professor in Medicine Faculty of Rennes University, Department of Gynaecology Obstetrics and Human Reproduction CHU Anne de Bretagne Rennes	42
Olivier Jourdain, MD Gynecologist Surgeon at Centre Gaïa Women Health, Président CME, Polyclinique Jean Villar Bordeaux France	43
Pierre Verger, Dr, Head of the South-Eastern Health Regional Observatory, South-Eastern Health Regional Observatory, Faculty of Medicine, Marseille, France	43
Patrice Mathevet, Head of the department of Gynecology. Full professor of Gynecology and Obstetrics, Centre Hospitalo-Universitaire Vaudois (University Hospital), avenue Pierre Decker 2, 1011 Lausanne, SWITZERLAND, INSERM, Unité 664, Faculté de Médecine Laënnec, Rue Guillaume Paradin 69372 Lyon cedex 08 FRANCE	44
Rouman Rozier, Gynécologie médicale, Institut Curie	45
Appendix A	46



Coverage based on HPVc F : HPV vaccination program coverage - last dose - females

Only countries where HPVc F coverage data was reported are shown.

Data sources:
http://www.who.int/immunization/monitoring_surveillance/data/HPV_estimates.xls accessed 10/2021; Data Flanders based on "Vaccinatiegraad in Vlaanderen 2016" Only data for 2012 and 2016 shown.

Unpublished data, do not copy or distribute



Bonanni P, et al. The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018-2019). *Expert Rev Vaccines*. Nov 2020

Table 5. List of WHO/ER countries with target VCR (n = 10).

Country	Target VCR (%, definition where available)	Monitored VCR	VCR range	Primary cohort gender	Target year	HPVv dose received	Primary cohort age
Portugal	85%, for 10–14 y/o girls	90%-94%*	○○○○	F	2018	≥2	2004–2006 birth cohort
Sweden	>90%	84%*	○○○○	F	2019	≥2	2006 birth cohort
UK	90%, for 13–14 y/o girls to receive 2 doses	84%*	○○○○	F	2018–2019	2	13–14 y/o (Grade 9)
Ireland	≥80, for girls to receive to receive 2 doses	72%*	○○○○	F	2016	2	12–13 y/o
Switzerland	80%, for girls and boys to receive 2 doses	60%*	○○○	F	2018	2	16 y/o
		17%	○	M	2018	NA	16 y/o
Luxembourg	80%, for the recommended population to receive 2 doses	56%*	○○○	F	2016	2	1991–2003 birth cohort
Italy	≥95%, for 11–12 y/o girls	50%*	○○	F	2017	2	2005 birth cohort
France	60%, for girls to receive complete regimen	24%*	○	F	2019	2	16 y/o
Bulgaria	75%	4%*	○	NA	2018	2	12–13 y/o
Greece	90%	NA	NA	NA	NA	NA	NA

Abbreviations: WHO/ER, WHO Europe; VCR, vaccination coverage rate; F, Female; M, Male; HPVv, Human papillomavirus vaccination; y/o, years old. NA, not available.

Legend: ○○○○ – High VCR (>70%); ○○○ – Moderate VCR (51–70%); ○○ – Low VCR (31–50%); ○ – Very low VCR (≤30%).

* VCR from national-level data source; in the case, dose-related VCR is specified, the VCR for the target population who received 2 doses is presented.

Only 4 of 10 countries reporting a VCR are in line with the WHO VCR for elimination.



This dashboard provides information about the status of HPV vaccine introduction in WHO Member States. As per the Global Strategy for Cervical Cancer Elimination, each country should introduce HPV in the national immunization schedule by 2030 and meet the target of 90% of girls fully vaccinated with HPV vaccine by age 15. Detailed information on the definition and data source of each indicator can be found in the Metadata page.



France



Global Map area


Country profile area

Select country

-
- Marshall Islands
- Mauritania
- Mauritius
- Mexico
- Micronesia (Federa...)
- Monaco
- Mongolia
- Montenegro
- Morocco
- Mozambique
- Myanmar
- Namibia
- Nauru
- Nepal
- Netherlands
- New Zealand
- Nicaragua
- Niger

National schedule	Year of introduction	Delivery strategy	Targeted Age	Targeted Sex	Interval between doses
Yes	2006	Facility-based	11-14	Both sexes	6 months

HPV vaccine, programme coverage in female



Meta data





HPV Prevention
and Control Board

www.hpvboard.org

Country Meeting

Prevention and control of HPV and HPV
related cancers in France: the current
landscape and way forward

2-3 December, 2021

VEYRIER-DU-LAC, ANNECY, FRANCE

Meeting objectives (1):

- **Discuss the healthcare system and prevention and control measures in France**
 - Review how prevention and control programs are organised within the French healthcare system
 - Provide a summary of the epidemiology, burden of disease and surveillance related to HPV and HPV related cancers in France.
- **Cervical cancer screening and treatment in France**
 - Give an overview of the current control measures in France
 - Discuss successes, topical issues and challenges related to HPV screening and treatment
 - Review the possible implementation of alternative screening methods and strategies such as self-sampling



Meeting objectives (2):

- **HPV vaccination in France**
 - Give an overview of the current HPV vaccination program
 - Discuss successes, topical issues and challenges related to HPV vaccination
 - Discussing the state of vaccine confidence, associated challenges and possible solutions to increase vaccine coverage rate.
 - Discuss the impact of Covid-19 pandemic on vaccine confidence and reviewing change of perception, beliefs and opinions towards vaccination
 - Discussing the efforts and stakeholders' involvement in social mobilisation and creating awareness.
- **Gain insight in the various stakeholder perspectives.**
- **Discuss the way forward.**



Practical Announcements

Please note that it's a hybrid meeting – we will appreciate that online and physical participants respect the time.

Physical Participants

- There is one mic on each table. Please use the mic on your table to ask the question. It will help the online participants to follow the questions and discussion in the meeting room

Online Participants

- Please switch on your video while introducing yourself and every time you speak
- Keep yourself on mute when not speaking
- Please make use of the chat function to ask any burning questions/comments or observations.

Physical and Online Participants

- We will open the breakout rooms closer to the session time and ask you to choose one based on your expertise and interest. We will appreciate that you keep your video on during the breakout group session, if your internet connection is stable.
- Breakout group chairs: please ensure that online and physical participants get opportunity to share their experience

